The effect of TNF? blockade in complicated, refractory Kawasaki disease
- 1 January 2006
- journal article
- case report
- Published by Taylor & Francis in Scandinavian Journal of Rheumatology
- Vol. 35 (4) , 318-321
- https://doi.org/10.1080/03009740600588228
Abstract
In Kawasaki disease (KD), a systemic vasculitis of childhood, serum levels of proinflammatory cytokines such as tumour necrosis factor α (TNFα) are elevated during the acute phase of the disease. Although the majority of children recover completely from a single dose of intravenous immunoglobulin (IVIG), the treatment is not always effective. In refractory cases of KD there are no documented treatment guidelines. A future role of biological agents directed against proinflammatory cytokines has recently been suggested by the American Heart Association (AHA). We describe two infants with severe KD, complicated by coronary as well as extracoronary aneurysms, who responded neither to repeated treatment with IVIG plus aspirin nor to corticosteroids. The children were subsequently treated with infliximab. In both cases, the effect was prompt and long‐lasting. Clinical improvement was seen within a few days after the first dose, and regression of the aneurysms occurred within weeks.Keywords
This publication has 14 references indexed in Scilit:
- Tumour necrosis factor inhibitors: risks and benefits in patients with rheumatoid arthritisInternal Medicine Journal, 2004
- Tuberculosis in a nine-year-old girl treated with infliximab for systemic juvenile idiopathic arthritisRheumatology, 2004
- Biologic Agents for the Treatment of Juvenile Rheumatoid ArthritisPediatric Drugs, 2004
- A polymorphism in the promoter of the CD14 gene (CD14/-159) is associated with the development of coronary artery lesions in patients with Kawasaki diseaseThe Journal of Pediatrics, 2003
- Successful treatment of resistant giant cell arteritis with etanerceptAnnals of the Rheumatic Diseases, 2003
- Tumor necrosis factor antagonist therapy and lymphoma development: Twenty‐six cases reported to the Food and Drug AdministrationArthritis & Rheumatism, 2002
- The Role of the Interleukin-1–Receptor Antagonist in Blocking Inflammation Mediated by Interleukin-1New England Journal of Medicine, 2000
- Endothelial Dysfunction Late After Kawasaki DiseaseCirculation, 1996
- Kawasaki disease in infants less than one year of ageThe Journal of Pediatrics, 1995
- Mice lacking the tumour necrosis factor receptor 1 are resistant to IMF-mediated toxicity but highly susceptible to infection by Listeria monocytogenesNature, 1993